296 related articles for article (PubMed ID: 20228274)
41. Stem cell gene transfer: insights into integration and hematopoiesis from primate genetic marking studies.
Dunbar CE
Ann N Y Acad Sci; 2005 Jun; 1044():178-82. PubMed ID: 15958711
[TBL] [Abstract][Full Text] [Related]
42. Genotoxicity of retroviral integration in hematopoietic cells.
Nienhuis AW; Dunbar CE; Sorrentino BP
Mol Ther; 2006 Jun; 13(6):1031-49. PubMed ID: 16624621
[TBL] [Abstract][Full Text] [Related]
43. Polyclonal fluctuation of lentiviral vector-transduced and expanded murine hematopoietic stem cells.
Maetzig T; Brugman MH; Bartels S; Heinz N; Kustikova OS; Modlich U; Li Z; Galla M; Schiedlmeier B; Schambach A; Baum C
Blood; 2011 Mar; 117(11):3053-64. PubMed ID: 21248062
[TBL] [Abstract][Full Text] [Related]
44. Medicine. Gene therapy--new challenges ahead.
Williams DA; Baum C
Science; 2003 Oct; 302(5644):400-1. PubMed ID: 14563994
[TBL] [Abstract][Full Text] [Related]
45. Lentiviral vector integration sites in human NOD/SCID repopulating cells.
Laufs S; Guenechea G; Gonzalez-Murillo A; Zsuzsanna Nagy K; Luz Lozano M; del Val C; Jonnakuty S; Hotz-Wagenblatt A; Jens Zeller W; Bueren JA; Fruehauf S
J Gene Med; 2006 Oct; 8(10):1197-207. PubMed ID: 16960916
[TBL] [Abstract][Full Text] [Related]
46. In-Vivo Gene Therapy with Foamy Virus Vectors.
Rajawat YS; Humbert O; Kiem HP
Viruses; 2019 Nov; 11(12):. PubMed ID: 31771194
[TBL] [Abstract][Full Text] [Related]
47. Clonal evidence for the transduction of CD34+ cells with lymphomyeloid differentiation potential and self-renewal capacity in the SCID-X1 gene therapy trial.
Schmidt M; Hacein-Bey-Abina S; Wissler M; Carlier F; Lim A; Prinz C; Glimm H; Andre-Schmutz I; Hue C; Garrigue A; Le Deist F; Lagresle C; Fischer A; Cavazzana-Calvo M; von Kalle C
Blood; 2005 Apr; 105(7):2699-706. PubMed ID: 15585650
[TBL] [Abstract][Full Text] [Related]
48. Gene therapy for primary immunodeficiencies: Part 1.
Cavazzana-Calvo M; Fischer A; Hacein-Bey-Abina S; Aiuti A
Curr Opin Immunol; 2012 Oct; 24(5):580-4. PubMed ID: 22981681
[TBL] [Abstract][Full Text] [Related]
49. Integrome signatures of lentiviral gene therapy for SCID-X1 patients.
Yan KK; Condori J; Ma Z; Metais JY; Ju B; Ding L; Dhungana Y; Palmer LE; Langfitt DM; Ferrara F; Throm R; Shi H; Risch I; Bhatara S; Shaner B; Lockey TD; Talleur AC; Easton J; Meagher MM; Puck JM; Cowan MJ; Zhou S; Mamcarz E; Gottschalk S; Yu J
Sci Adv; 2023 Oct; 9(40):eadg9959. PubMed ID: 37801507
[TBL] [Abstract][Full Text] [Related]
50. Lymphomagenesis in SCID-X1 mice following lentivirus-mediated phenotype correction independent of insertional mutagenesis and gammac overexpression.
Ginn SL; Liao SH; Dane AP; Hu M; Hyman J; Finnie JW; Zheng M; Cavazzana-Calvo M; Alexander SI; Thrasher AJ; Alexander IE
Mol Ther; 2010 May; 18(5):965-76. PubMed ID: 20354504
[TBL] [Abstract][Full Text] [Related]
51. Foamy viral vector integration sites in SCID-repopulating cells after MGMTP140K-mediated in vivo selection.
Olszko ME; Adair JE; Linde I; Rae DT; Trobridge P; Hocum JD; Rawlings DJ; Kiem HP; Trobridge GD
Gene Ther; 2015 Jul; 22(7):591-5. PubMed ID: 25786870
[TBL] [Abstract][Full Text] [Related]
52. Review: Oncogenic Insertional Mutagenesis as a Consequence of Retroviral Gene Therapy for X-Linked Severe Combined Immunodeficiency Disease.
Ahmed B; Zafar M; Qadir MI
Crit Rev Eukaryot Gene Expr; 2019; 29(6):511-520. PubMed ID: 32422006
[TBL] [Abstract][Full Text] [Related]
53. A novel model of SCID-X1 reconstitution reveals predisposition to retrovirus-induced lymphoma but no evidence of gammaC gene oncogenicity.
Scobie L; Hector RD; Grant L; Bell M; Nielsen AA; Meikle S; Philbey A; Thrasher AJ; Cameron ER; Blyth K; Neil JC
Mol Ther; 2009 Jun; 17(6):1031-8. PubMed ID: 19337236
[TBL] [Abstract][Full Text] [Related]
54. Reducing the genotoxic potential of retroviral vectors.
Ramezani A; Hawley TS; Hawley RG
Methods Mol Biol; 2008; 434():183-203. PubMed ID: 18470646
[TBL] [Abstract][Full Text] [Related]
55. Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking.
Kustikova O; Fehse B; Modlich U; Yang M; Düllmann J; Kamino K; von Neuhoff N; Schlegelberger B; Li Z; Baum C
Science; 2005 May; 308(5725):1171-4. PubMed ID: 15905401
[TBL] [Abstract][Full Text] [Related]
56. [Development and application of gene therapy technologies].
Ozawa K
Uirusu; 2004 Jun; 54(1):49-57. PubMed ID: 15449904
[TBL] [Abstract][Full Text] [Related]
57. Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency.
Thornhill SI; Schambach A; Howe SJ; Ulaganathan M; Grassman E; Williams D; Schiedlmeier B; Sebire NJ; Gaspar HB; Kinnon C; Baum C; Thrasher AJ
Mol Ther; 2008 Mar; 16(3):590-8. PubMed ID: 18180772
[TBL] [Abstract][Full Text] [Related]
58. The MDS1-EVI1 gene complex as a retrovirus integration site: impact on behavior of hematopoietic cells and implications for gene therapy.
Métais JY; Dunbar CE
Mol Ther; 2008 Mar; 16(3):439-49. PubMed ID: 18227842
[TBL] [Abstract][Full Text] [Related]
59. Tracking of specific integrant clones in dogs treated with foamy virus vectors.
Ohmine K; Li Y; Bauer TR; Hickstein DD; Russell DW
Hum Gene Ther; 2011 Feb; 22(2):217-24. PubMed ID: 20738155
[TBL] [Abstract][Full Text] [Related]
60. Retroviral vectors: post entry events and genomic alterations.
Nowrouzi A; Glimm H; von Kalle C; Schmidt M
Viruses; 2011 May; 3(5):429-55. PubMed ID: 21994741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
